2018 Traveler’s Diarrhea Drug Development- Pipeline Analysis Report
Traveler’s Diarrhea is a common gastrointestinal disease with loose stools and abdominal cramps. It is mostly caused by E. coli bacteria. Africans and South Asian population is mostly susceptible to the disease.
Around 10 companies and universities are focusing on developing treatment options for Traveler's Diarrhea.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Traveler's Diarrhea pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Traveler's Diarrhea pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Traveler's Diarrhea pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Around 10 companies and universities are focusing on developing treatment options for Traveler's Diarrhea.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Traveler's Diarrhea pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Traveler's Diarrhea pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Traveler's Diarrhea pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 TRAVELER’S DIARRHEA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Traveler’s Diarrhea Pipeline Snapshot
2.3 Traveler’s Diarrhea Pipeline by Phase
2.4 Traveler’s Diarrhea Pipeline by Company
2.5 Traveler’s Diarrhea Pipeline by Mechanism of Action
3 TRAVELER’S DIARRHEA- COMPANY WISE PIPELINE ANALYSIS
Cosmo Pharmaceuticals
Nippon Shinyaku Co., Ltd.
Prokarium Limited
Scandinavian Biopharma
Sigmoid Pharma Limited
UAS LABORATORIES
4 TRAVELER’S DIARRHEA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN TRAVELER’S DIARRHEA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 TRAVELER’S DIARRHEA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Traveler’s Diarrhea Pipeline Snapshot
2.3 Traveler’s Diarrhea Pipeline by Phase
2.4 Traveler’s Diarrhea Pipeline by Company
2.5 Traveler’s Diarrhea Pipeline by Mechanism of Action
3 TRAVELER’S DIARRHEA- COMPANY WISE PIPELINE ANALYSIS
Cosmo Pharmaceuticals
Nippon Shinyaku Co., Ltd.
Prokarium Limited
Scandinavian Biopharma
Sigmoid Pharma Limited
UAS LABORATORIES
4 TRAVELER’S DIARRHEA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN TRAVELER’S DIARRHEA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Traveler’s Diarrhea Pipeline by Phase, H1- 2018
Figure 2: Traveler’s Diarrhea Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Traveler’s Diarrhea Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Traveler’s Diarrhea Pipeline by Phase, H1- 2018
Figure 2: Traveler’s Diarrhea Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Traveler’s Diarrhea Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Traveler’s Diarrhea Pipeline by Phase, H1- 2018
Table 2: Traveler’s Diarrhea Pipeline by Companies, H1- 2018
Table 3: Traveler’s Diarrhea Pipeline by Mechanism of Action, H1- 2018
Table 4: Cosmo Pharmaceuticals Traveler’s Diarrhea pipeline, May 2018
Table 5: Nippon Shinyaku Co., Ltd. Traveler’s Diarrhea pipeline, May 2018
Table 6: Prokarium Limited Traveler’s Diarrhea pipeline, May 2018
Table 7: Scandinavian Biopharma Traveler’s Diarrhea pipeline, May 2018
Table 8: Sigmoid Pharma Limited Traveler’s Diarrhea pipeline, May 2018
Table 9: UAS LABORATORIES Traveler’s Diarrhea pipeline, May 2018
Table 1: Traveler’s Diarrhea Pipeline by Phase, H1- 2018
Table 2: Traveler’s Diarrhea Pipeline by Companies, H1- 2018
Table 3: Traveler’s Diarrhea Pipeline by Mechanism of Action, H1- 2018
Table 4: Cosmo Pharmaceuticals Traveler’s Diarrhea pipeline, May 2018
Table 5: Nippon Shinyaku Co., Ltd. Traveler’s Diarrhea pipeline, May 2018
Table 6: Prokarium Limited Traveler’s Diarrhea pipeline, May 2018
Table 7: Scandinavian Biopharma Traveler’s Diarrhea pipeline, May 2018
Table 8: Sigmoid Pharma Limited Traveler’s Diarrhea pipeline, May 2018
Table 9: UAS LABORATORIES Traveler’s Diarrhea pipeline, May 2018
